Supplementary Figure S2. Effect of GM-CT-01 on the capacity of CD8+ TIL to degranulate. (A & B) CD8+ TIL were isolated from ascites obtained from ovarian carcinoma patient LB3015 and pancreatic carcinoma patient LB3033. (C & D) CD8+ T cells were isolated from blood samples obtained from donors LB2110 and LB678 without cancer. CD8+ T cells (75,000) were treated for 20 h with 1.8 μM GM-CT-01 or 5 mM LacNAc, washed and stimulated for 5 h in IMDM 2% HS AAG with either 150,000 P815 cells previously incubated for 15 min with an anti-CD3 antibody (OKT3, Mabtech 1 μg/ml), or with 75,000 CD3/CD28 beads (Ibexogen). Brefeldin-A (5 μg/ml, Sigma) and FITC-coupled anti-CD107a+b (1/100, BD), or the control isotype (IgG1, BD), were also added. After 5 h of stimulation, cells were washed, labeled for 15 min at 4°C with anti-CD3 PerCP (1/40 SK1, BD) and anti-CD8 APC (1/40 RPA-T8, BD) antibodies, washed and fixed in PBS-PFA 1%. Events shown are CD3+CD8+ cells. In the histogram plots, surface expression of CD107 is indicated as the percentage of the cells having a fluorescence intensity above 99% of the cells labeled with the control isotype-matched antibody (grey histogram). The dot plot panels show in red the cells considered as CD107a+b-negative and in blue the cells considered as CD107a+b-positive.